(C) 2011 Elsevier Inc All

(C) 2011 Elsevier Inc. All FK228 Cytoskeletal Signaling inhibitor rights reserved. Semin Arthritis

Rheum 41:455-460″
“One new tetraoxygenated xanthone, merguensinone (1), along with one known xanthone, 1,5,6-trihydroxy-2-prenyl-6′,6′-dimethyl-2H-pyrano(2′,3′: 3,4)xanthone (2) and five known biflavanoids, (-)-GB-1a (3), ( )-GB-2a (4), (+)-morelloflavone (5), (+)-volkensiflavone (6), and amentoflavone (7) were isolated from the methanol extract from the twigs of Garcinia merguensis. Their antibacterial activity against the standard Staphylococcus aureus ATCC 25923 and methicillin-resistant S. aureus and antioxidation activity with DPPH center dot assay were examined. (C) 2013 Phytochemical Society of Europe. Published by Elsevier B.V. All rights reserved.”
“P>A woman with oculocutaneous Behcet disease developed primary tuberculosis while being treated with infliximab. A latent tuberculosis infection had been excluded before therapy. After more than 80 weeks of treatment, the patient complained of fevers, night sweats, shivering and vigorous cough. The chest x-ray showed miliary shadowing.

Mycobacterium tuberculosis Dibutyryl-cAMP molecular weight was identified. The history revealed recent contact to an individual with smear-positive tuberculosis. This constellation speaks in favor of a de novo tuberculosis infection with a fulminant course.”
“Objectives: To review pulmonary arteritis (PA) complicated by pulmonary arterial hypertension (PAH) in Takayasu’s arteritis (TA).

Methods: Two cases of PA and PAH in TA patients and similar cases published in the Medline database from 1975 to 2009 were reviewed.

Results: Forty-six cases (females 89.1%, Asians 65%, mean

age 34.6 years) were analyzed, 42.2% of which Crenigacestat molecular weight had PAH. Isolated PA was reported in 31.8%. Respiratory symptoms were presented as dyspnea (75.5%), chest pain (48.9%), hemoptysis (42.2%), and cough (17.7%). Hypertension, vascular bruits, and diminished/absent pulses were reported in 48.9% of patients. A diagnosis of PA was based on abnormal uptake on pulmonary perfusion scan and a finding of stenosis, narrowing, occlusion, and irregularity on computed tomography or magnetic resonance imaging, and/or pulmonary angiography. Patients were treated with glucocorticoids (77.5%), disease-modified antirheumatic drugs (35%), and warfarin (20%); only a few were treated with biological agents. Vascular procedures were performed in 52.5% of cases, on pulmonary arteries in 37.5% with good results. The outcome was death in 20.5% of PA patient and 33.3% in PAH patients.

Conclusions: TA may be complicated by life-threatening PA and PAH. Clinical signs are not specific and may be masked by involvement of the aorta and its branches. Treatment with glucocorticoids and disease-modified antirheumatic drugs has only partial effect, which may be intensified by biological agents. Invasive procedures on pulmonary arteries may be a complementary option.

Comments are closed.